ANNUAL REPORT 2012 - TiGenix

Biologics for treatment of Rheumatoid Arthritis and other Autoimmune Diseases
Biologics are currently standard of care for the treatment of RA as well as various other
autoimmune-mediated inflammatory diseases. The overview below lists the key biologics currently
on the market to treat autoimmune diseases together with the associated revenues for 2011.
Indication
incidence (per 100.000)
RA
23
MS
4-6
SS
1-2
LUP
1-10
PSO
80-240
JIA
2-20
AS
1-14
IBD/CD
900/700
2011
Revenues
Infliximab/Remicade (J&J)
$ 8.5 Bn
Humira (Abbott)
$ 7.9 Bn
Enbrel (Pfizer)
$ 3.7 Bn
Betaferon (Bayer)
$ 1.6 Bn
Tysabri (Biogen/Idec)
$ 1.5 Bn
Orencia (Bristol-Myers Squibb)
$ 917 Mn
Cimzia (UCB)
$ 423 Mn
Benlista (GSK) *
$ 52 Mn
*
FDA approval in March 2011; EMA approval in July 2011.
RA : Rheumatoid Arthritis; MS Multiple Sclerosis; Systemic Sclerosis; LUP : Lupus; PSO : Psoriasis; JIA : Juvenile Idiopathic Arthritis; AS :
Ankylosing spondylitis; IBD : Inflammatory Bowel Disease; CD : Crohn’s Disease; Source : “Research and Markets”, company websites.
6.6. FACILITIES
Manufacturing facility in the Netherlands
Headquarter and other facilities in Belgium
The Company’s registered and main office,
based in the Romeinse straat 12, box 2, 3001
Leuven, Belgium, is currently leased pursuant
to a lease agreement.
The Company’s Belgian R&D facility, which
used to be housed in the same building as
the headquarters, has been closed and
R&D activities have been centralized in the
Madrid facilities, Spain.
The Company has built a new manufacturing
site in Geleen, the Netherlands. As a
consequence of the currently ongoing
transfer of the Company’s manufacturing
activities to this new manufacturing site, it
intends to terminate its lease for its smaller
Leuven production facility around the end of
April 2013.
In anticipation of the growing demand for
ChondroCelect and the expansion of the
product pipeline, TiGenix secured increased
production capacity in Europe. On June
26, 2009, TiGenix B.V. entered into a long
term lease agreement with DSM Nederland
B.V. (acting through its Chemelot ® division,
acting on behalf of DSM Research B.V.) for
a building on the Chemelot Campus in
Geleen (near Maastricht), the Netherlands.
This manufacturing site in Geleen (“MSG”)
is located at Urmonderbaan 20b, RD 6167
Geleen, the Netherlands.
The initial term of the lease runs until July 31,
2029, it being understood that TiGenix B.V.
can terminate the agreement as of July 31,
2019 with a three year notice. After the initial
term, the term can be extended with periods
of five years, and both parties can terminate
the lease with a two year notice. Effective
71